Would you offer adjuvant chemotherapy to a patient with high grade pT1 bladder cancer with concurrent pT2 prostatic urethral stroma involvement?

I would adopt the data from the CheckMate 274 trial. If the patient is post-neoadjuvant cisplatin-based chemotherapy, I would consider adjuvant nivolumab, especially if the tumor PD-L1 is high and/or post-op ctDNA is positive for minimal residual disease. If the patient has not received neoadjuvant ...